The Legacy Collection/THA/Shutterstock(SeaPRwire) - 自Star Wars成长为全球现象级大作以来，人们很容易忘记这个系列最初（相对而言）是白手起家的。虽然将原版Star Wars称为“独立电影”并不完全准确——它由主流制片厂20th Century Fox发行——但卢卡斯本人自筹了1977年首部《星球大战》电影（后来被赋予副标题A New Hope）的大部分资金，并使用遮罩绘画、微缩模型和从其他电影中重复使用的道具，将预算控制在相对紧张的1100万美元以内。他是怎么做到的？部分原因是运用了他在第一部电影THX 1138中学到的东西。尽管同样是科幻题材，THX 1138与Star Wars是截然不同的类型。这部以对话为主导的电影远非热闹的太空歌剧，而是对该类型采取了更具思辨性和哲学性的手法。声音设计师兼联合编剧Walter Murch告诉Indiewire：“我们的想法是突破可理解性的界限，将这部电影说成是来自另一种文化、不知何故在1970年登陆的作品。”THX（发音为“Tex”）是主角的分类前缀，由已故的伟大演员Robert Duvall饰演——他没有正式名字，只有时刻佩戴的徽章编号（1138）。影片设定在一个高效到极致的未来，人类情感被禁止，公民被严格要求服用麻醉剂，目的是让他们尽可能顺从。这一切非常像1984，尽管卢卡斯的预测略有偏差：他认为是国家而非企业用“购买并快乐”这样的口号麻痹公众。不吃药——而且药的种类很多，颜色和大小各异——可能会导致这个没有灵魂的未来反乌托邦中一个有生产力的公民出现“严重的化学失衡”。在这里，这基本上意味着意识到只为工作和消费而存在的生活的空虚，THX 1138在影片早期就意识到了这一点。随后，他与室友LUH 3417（Maggie McOmie饰演）坠入（严令禁止的）爱河，引发了一系列事件，导致THX被捕并最终逃离极权现实。角色们在设计简单的隔间中向OMM“忏悔”，这些隔间将静态图像与录音配对，完美地唤起了这种国家认可的宗教的冷漠感。这是影片极简主义风格的典型体现：THX 1138最具戏剧性的场景发生在工业走廊和几乎没有布景装饰的空白白色房间里，营造出一个禁止个人财产和兴趣的缺乏生气、令人窒息的世界。发型、妆容和服装也保持简单：所有演员都穿着相同的白色连体服，并且被要求为影片剃光头，这在幕后特辑Bald: The Making of THX 1138中有记录。这些成本削减措施（考虑到主题，颇具讽刺意味）与一些壮观的镜头相结合，这些镜头使用微缩模型和遮罩绘画——两种相对经济的实拍特效技术——来扩展影片的世界。这种巧妙的变通方法和手工细节的结合，在风格和技术上都将THX 1138与Star Wars: A New Hope联系起来：例如，在THX中，巡逻城市的可牺牲步兵穿着60年代风格的皮革警服和僵硬、闪亮的银色面具。从视觉上看，他们介于3PO机器人和Stormtrooper之间，制作它们的方法基本相同。George Lucas和Maggie McOmie在THX 1138的片场。| Sunset Boulevard/Corbis Historical/Getty Images在THX 1138中还有卢卡斯最著名作品的其他痕迹：例如，将全息图用作信使和娱乐工具，更不用说其中一个无脸赛博警察说的台词：“I think I ran over a Wookiee back there on the expressway.”然而，最重要的是，这部电影让乔治·卢卡斯学会了艰苦奋斗，给他的经验让他后来能够将一部预算不高的科幻复古作品变成有史以来最大、最具影响力的电影系列之一。当然，这都是事后的看法。1971年，THX 1138被认为是一次雄心勃勃的失败，获得了平庸的评价和糟糕的票房。Warner Bros.对这部电影非常不满，以至于终止了与American Zoetrope的协议，要求Coppola偿还该公司已投资于未来项目的资金。这让Coppola背负了40万美元的债务，迫使他接受了执导The Godfather的工作。就卢卡斯而言，他在THX 1138之后暂时告别科幻片，执导了American Graffiti，并开始习惯自己的电影赚钱。但多亏了他在第一部故事片上的经验，当他回归该类型时，结果吸引了全世界数百万人的想象力。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。
分类: 头条新闻,日常新闻
SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。THX 1138可在主要流媒体平台上付费租赁。
HONG KONG, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the “REIT”; stock code: 405) announced its annual results for the year ended 31 December 2025.Yuexiu REIT Management Team: Chairman and Non-Executive Director Mr. JIANG Guoxiong (center), Executive Director and Chief Executive Officer Ms. OU Haijing (left), and Chief Financial Officer Mr. KWAN Chi Fai (right)2025 Annual Results Highlights: - Overall operation remained resilient, with total revenue of RMB1,856 million (2024: RMB2,032 million).- The average financing cost was 3.61%, a three-year low; the average interest payment rate was 3.77%, representing a year-on-year decrease of 76 basis points. Excluding exchange loss, the financing expenses decreased by approximately RMB152 million year-on-year.- As at 31 December 2025, the overall occupancy rate of the properties was 82.1% (2024: 84.5%).- Optimised the asset portfolio by disposing of a 50% interest in Yuexiu Financial Tower in Q4 2025, realising cash proceeds of approximately RMB5.3 billion to enhance financial flexibility. Yuexiu REIT maintained its "investment-grade" rating from both Standard & Poor's and Fitch, with the outlook upgraded to "stable".- The final distribution to the Unitholders for the period will be approximately RMB0.0189, equivalent to HK$0.0214. Distribution per Unit for the year will be approximately RMB0.0522, equivalent to HK$0.0580. Distribution yield is 6.74% per Unit for the year.- To maintain the REIT’s financial flexibility, the distribution ratio for the period from 1 July 2025 to 31 December 2025 has been adjusted to 90%, resulting in an overall full-year distribution ratio of approximately 96%.Guangzhou International Finance Center (GZIFC):- Operating revenue of the GZIFC complex was RMB984 million, accounting for 53.0% of the REIT’s total revenue.- The office building of GZIFC introduced two Fortune Global 500 companies; the occupancy rate was 80.9%.- GZIFC Shopping Mall introduced China Duty Free Group (CDFG), the first and currently the only downtown duty-free store in Guangzhou, achieving a renewal rate of 89% for the year, and an occupancy rate of 95.5% at the end of the period.- Four Seasons Hotel Guangzhou's average room rate increased by 5.8% year-on-year. Ascott Serviced Apartments GZIFC achieved an average occupancy rate of 91.5%, up 1 percentage point year-on-year, with revenue reaching a record high for the period.Proactive Management of Financing Risk and Effective Stabilisation of Financing Cost- With regard to the short-term loan of RMB530 million, the 5-year syndicated loan of HK$2.1 billion, and the remaining HK$2.1 billion of the 3-year syndicated loan of HK$3.8 billion, all due in 2025, the Manager in 2025 renewed the short-term loan of RMB530 million, obtained offshore loan of RMB1.7 billion, issued dim sum bonds of RMB1 billion, and obtained an offshore syndicated loan package equivalent to HK$2.1 billion (a sustainability-linked loan), for the refinancing of the maturing loans so as to ensure effective monitor on the liquidity risk.- A total of approximately RMB4.68 billion in loans were obtained in 2025 to partially refinance offshore HKD floating rate loans, taking advantage of the relatively low-cost of RMB financing to proactively adjust the financing structure. At the end of 2025, the financing interest rate exposure of Yuexiu REIT was approximately 10%, narrowed by 16 percentage points from 26% at the beginning of the year; the average financing cost was 3.61%, a three-year low, representing a decrease of 55 basis points from 4.16% at the beginning of the year; the average interest payment rate for the full year of 2025 was 3.77%, representing a year-on-year decrease of 76 basis points. Excluding the exchange loss, the finance expenses were approximately RMB773 million, representing a year-on-year decrease of approximately RMB152 million.- As at the end of 2025, Yuexiu REIT had RMB financing of approximately RMB15.47 billion, accounting for 76% of total financing (2024: RMB financing of approximately RMB12.33 billion, accounting for 60% of total financing).Mr. JIANG Guoxiong, Chairman and Non-Executive Director of Yuexiu REIT, said, "2025 marked the 20th anniversary of Yuexiu REIT's listing. The Manager consolidated its competitive advantages by taking strategic actions to secure market share, prioritised occupancy rates, strengthened risk control to stabilise lease renewals, enhanced product competitiveness to meet market demand and invested in capital renovation projects to ensure asset value preservation and appreciation. These efforts stabilised the fundamentals of operations in a challenging market, providing solid support for the full-year revenue. Concurrently, we optimised the asset portfolio by appropriately reducing the proportion of office buildings, and proactively captured favourable financing opportunities, successfully issuing the first-ever Panda Bonds by a listed REIT globally as well as the REIT’s inaugural green bond. Financing costs for the year reached a three-year low, effectively underpinning the overall distribution level. The successful execution of a series of pioneering capital operations fully demonstrated the Manager’s strategic commitment to driving the high-quality development of Yuexiu REIT. This underscored its resolute determination in creating sustainable and long-term value for Unitholders.”Guangzhou International Finance Center (GZIFC)During the year, GZIFC recorded a newly contracted area of 15,702 sq.m. The newly launched 7,403 sq.m. of furnished units recorded an absorption cycle of about 36 days, with an absorption rate close to 72%. Quality tenants introduced include two Fortune Global 500 companies, a Fortune China 500 company, a leading global shipping giant, and a renowned Internet-based culture, sports and entertainment company. In addition, the project recorded a renewal area of 34,294 sq.m. and a renewal rate of 86%, retaining quality tenants including six Fortune Global 500 companies and a foreign consulate. GZIFC was selected as one of the Top 30 companies in the “Performance Index - 2025 Commercial Property Operation Performance)” by Guandian.GZIFC Shopping Mall renewed lease with its anchor tenant, Guangzhou Friendship Store, and introduced China Duty Free Group (CDFG) to set up a store, which is the first and currently the only downtown duty-free store in Guangzhou. In addition, GZIFC Shopping Mall launched the light meal and beverage area on the basement floor, coupled with the brand revitalisation of the dining tenants on the fourth and fifth floors by introducing seven “first stores”. Membership operations achieved remarkable results, with the share of member sales doubling to 16%. The project actively created digitalised consumption scenarios and made full use of mainstream platforms to attract customer flow through multiple channels. Specifically, the “Italian Culture Season” themed event was successfully held in collaboration with hotels, theaters, museums and consulates, effectively boosting customer flow and sales. Newly contracted area and renewal area totaled 35,573 sq.m., with a renewal rate of 89%. The occupancy rate was 95.5%.Four Seasons Hotel Guangzhou launched the first batch of renovated rooms during the year. The average room rate was RMB2,260, representing a year-on-year increase of 5.8%. The average occupancy rate was 77.7%. The revenue per available room (RevPAR) was RMB1,756, representing a year-on-year increase of 0.9%. The RevPAR competitive index was 110.0, maintaining a relatively leading market position among luxury hotel competitors. Ascott Serviced Apartments GZIFC recorded an average occupancy rate of 91.5% during the year, representing a year-on-year increase of 1 percentage point. The average room rate was RMB1,137, representing a year-on-year increase of 1.6%. The RevPAR was RMB1,040, representing a year-on-year growth of 2.7%. The RevPAR competitive index reached 146.9, remaining at a high level among high-end apartment competitors. The Apartments achieved a record high in operating revenue for the same period and ranked first in operating revenue among Ascott China properties for ten consecutive years since 2016.Yuexiu Financial TowerThe Manager disposed of 50% interest in Yuexiu Financial Tower in Q4 2025. Following completion of the disposal, Yuexiu Financial Tower became a Qualified Minority-owned Property of the REIT. The occupancy rate was 77.9% at the end of the period.White Horse BuildingWhite Horse Building introduced high-quality customers from core industrial clusters in Guangzhou, Shenzhen and Dongguan and recorded a newly contracted area of 5,808 sq.m. for the year, with full occupancy on the 1st floor for the first time in the past five years and a six-year record high set by the 2nd floor’s occupancy rate. During the year, it organised 22 original brands to showcase their products at professional exhibitions such as the Fashion World Tokyo, and the China International Fashion Fair; held the “White Horse Fashion Journey: Border Trade Supply Chain Matching Conference”, and established the “Guangdong-Xinjiang Fashion Industry Chain Supply and Procurement Cooperation Alliance” with ten wholesale markets in Urumqi, Xinjiang. During the year, it welcomed a total of 517 procurement delegations, along with nearly 13,000 purchaser visits, including 19 foreign delegations from France, Vietnam and other countries, and facilitated procurement deals worth RMB320 million. The occupancy rate was 96.0% at the end of the period.Fortune PlazaDuring the year, the project recorded a newly contracted area of 6,334 sq.m., and introduced certain quality tenants including several subsidiaries of a Fortune Global 500 integrated financial group, two Fortune Global 500 companies and the Guangzhou branch of two global leading companies. The project recorded a renewal area of 8,662 sq.m. and a renewal rate of 84.0%, retained quality tenants including three Fortune Global 500 companies and the Guangzhou branch of a national commercial bank. Upgraded product standards accelerated the absorption of vacant units, with an absorption rate of 93% for furnished units. The occupancy rate was 93.4% at the end of the period, representing a year-on-year increase of 1 percentage point, and a strong rebound of 5.4 percentage points from the interim period.City Development PlazaDuring the Reporting Year, the project recorded a newly contracted area of 9,279 sq.m. and introduced a beauty technology company and a pharmaceutical supply chain service company to enhance the ambience of healthcare business in the building. The project recorded a renewal area of 5,011 sq.m. and a renewal rate of 77%, retained tenants including a Fortune Global 500 company and a globally-renowned Contract Research Organisation (CRO). The occupancy rate was 90.6% at the end of the period.Victory PlazaVictory Plazq’s anchor tenant, Uniqlo, continued to play a flagship role, recording a 7.0% year-on-year sales growth for the year and maintaining its position as the top-selling store nationwide. The project successfully introduced the sports brand “Super Anta” to set up the largest store in the Guangzhou-Foshan region and “Crab Mang Mang”, the first store nationwide of Guizhou spicy crab business, achieved the diversification of its food and beverage brand portfolio. By connecting internal and external resources to hold fifteen major events, the mall achieved a year-on-year increase of 2.0% in its annual sales. During the year, newly contracted area and renewal area totaled 5,579 sq.m., with a renewal rate of 84%. The occupancy rate was 94.0% at the end of the period.Shanghai Yue Xiu TowerDuring the year, Shanghai Yue Xiu Tower recorded a renewal area of 6,430 sq.m., with a renewal rate of 43%, while securing a newly contracted area of 8,070 sq.m., efficiently making up for the prematurely vacated units. During the year, the project continued to increase the supply of small-area furnished units to meet market demand, formulated differentiated pricing strategies, and successfully held a channel recruitment conference, which attracted more than one hundred real estate agencies. By investing in various capital nature renovations, the project enhanced both energy efficiency and service standards. The occupancy rate was 83.1% at the end of the period.Wuhan PropertiesDuring the year, Wuhan Yuexiu Fortune Centre recorded a newly contracted area of 26,837 sq.m., and introduced quality tenants including two Fortune Global 500 state-owned enterprises, and two Fortune Global 500 foreign enterprises. In addition, it recorded a renewal area of 20,617 sq.m. and a renewal rate of 76.0%, hitting a new high in the past three years, and retained quality tenants, including seven Fortune Global 500 enterprises and a Fortune China 500 company. Approximately 21,000 sq. m. of renovated units were supplied throughout the year, with an absorption rate approaching 98%. The occupancy rate was 62.1% at the end of the period, representing a year-on-year increase of 1 percentage point.Wuhan Starry Victoria Shopping Centre revitalised several popular dining and fitness brands, aiming to attract more family and young customer groups. The project deeply tapped into the consumption potentials of “night economy” and “scene experience” by leveraging the unique venue feature of “Joy Garden”, launching themed activities such as “Riverside Starry Night ”, thus achieving customer flow substantially in line with last year, while the shopping mall recorded a year-on-year increase of 0.5% in annual sales. During the year, newly contracted area and renewal area totaled 9,827 sq.m., with a renewal rate of 48.0%. The occupancy rate was 87.4% at the end of the period, representing a rebound of 5.0 percentage points from the interim period.Hangzhou VictoryDuring the year, the project recorded a newly contracted area of 7,890 sq.m. and introduced a tenant to take up an entire floor. In addition, it recorded a renewal area of 8,836 sq.m. and a renewal rate of 54%, retained quality tenants including two Fortune Global 500 companies and the Zhejiang branch of a state-owned enterprise in Shanxi Province. The occupancy rate was 84.5% at the end of the period.Integrating ESG into Business and Promoting Sustainable DevelopmentAdhering to a long-term perspective, the Manager systematically advanced ESG initiatives. On the occasion of publicly disclosing Yuexiu REIT’s sustainability practices for the tenth consecutive year, the Manager officially renamed the “Environmental, Social and Governance Report” to the “Sustainability Report”, further promoting the deep integration of Yuexiu REIT’s strategy into sustainable development and reinforcing their synchronized progress. During the year, Yuexiu REIT received the highest Green Five Star rating and the title of “Global Sector Leader” for the first time from the Global Real Estate Sustainability Benchmark (GRESB) and once again secured A-rating (highest level) for public disclosure, highlighting its outstanding capabilities in the field of sustainable development.ProspectsIn the coming year, the Manager will maintain a prudent and optimistic attitude, adapt proactively to changes and strengthen risk managemen to generate stable return for the Unitholders. In terms of asset management, the Manager will dynamically implement proactive, prudent and flexible leasing and operating strategies in response to economic development trends and competitive dynamics, diligently explore new growth drivers, and keenly seize potential opportunities to enhance the market competitiveness of asset portfolio. In terms of financing management, the Manager will continue to review and make reasonable adjustments to its financing structure, and introduce low-cost RMB financing through various financing channels to offset interest rate risks. In respect of renovation projects, the Manager will carry out the phased renovations of Four Seasons Hotel Guangzhou in an orderly manner to support the long-term preservation and appreciation of property value.About Yuexiu Real Estate Investment TrustYuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. As of 31 December 2025, Yuexiu REIT’s portfolio of properties consisted of ten properties (including one Qualified Minority-owned Property), namely, White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Guangzhou International Finance Centre (“GZIFC”), Yuexiu Financial Tower (a Qualified Minority-owned Property with a 49.495% beneficial interest) located in Guangzhou; Yue Xiu Tower located in Shanghai; Wuhan Yuexiu Fortune Centre, and Starry Victoria Shopping Centre located in Wuhan; Victory Business Centre located in Hangzhou; and Yue Xiu Building located in Hong Kong. The total gross floor area of the properties (excluding Yuexiu Financial Tower) was approximately 974,000 sq.m. All properties are located in the central business district of Guangzhou, Shanghai, Wuhan, Hangzhou and Hong Kong respectively. The categories of the properties include Grade-A offices, commercial complexes, retail business, hotel, serviced apartments and professional clothing market etc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, March 11, 2026 - (ACN Newswire via SeaPRwire.com) – March 9, Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. According to reports, on the day the first prescription was issued in mainland China, VELSIPITY(R) was simultaneously prescribed in eight tertiary hospitals across seven key cities—Guangzhou, Shanghai, Hangzhou, Xi’an, Chongqing, Beijing, and Nanjing—achieving immediate coverage of patients in major regions nationwide on its launch day. The drug has also expanded patient access through internet hospital platforms. To date, patients at leading medical institutions, including the First Affiliated Hospital of Sun Yat-sen University, Sir Run Run Shaw Hospital, the First Affiliated Hospital of the Air Force Medical University of the People's Liberation Army, Chongqing People’s Hospital, and Peking Union Medical College Hospital, have already benefited from the therapy.Notably, VELSIPITY(R) was approved for marketing by China’s National Medical Products Administration (NMPA) in February this year. The first prescription in mainland China was issued just one month later, marking a rollout significantly faster than the industry average. Industry observers believe this not only reflects the strong clinical demand for the product but also demonstrates Everest Medicines’ execution capabilities in the commercialization of innovative drugs.From a disease burden perspective, inflammatory bowel disease (IBD) is considered one of the fastest-growing gastrointestinal diseases worldwide. IBD mainly includes ulcerative colitis (UC) and Crohn’s disease (CD). In recent years, the number of patients in China has continued to increase, driven by changes in dietary patterns, shifts in lifestyle, and improvements in diagnostic capabilities. Several industry research institutions predict that China’s IBD treatment market could exceed RMB 10 billion by around 2030, with novel small-molecule innovative drugs expected to become one of the key drivers of market growth.From a clinical perspective, ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by symptoms such as mucus and blood in the stool, abdominal pain, diarrhea, and rectal tenesmus, which can significantly affect patients’ quality of life. In China, both the incidence and prevalence of UC are increasing, with a clear trend toward younger patients. The patient population is projected to grow from approximately 0.98 million in 2025 to about 1.50 million by 2031. As the disease remains incurable, patients require long-term management to maintain disease control.VELSIPITY(R) is a next-generation, highly selective S1P receptor modulator with best-in-disease potential and strong first-line treatment recommendations for moderately to severely active ulcerative colitis (UC) in both the American Gastroenterological Association (AGA) Clinical Practice Guideline and the American College of Gastroenterology (ACG) Clinical Guideline Update.Results from multiple global clinical studies have demonstrated that VELSIPITY(R) delivers meaningful clinical benefits, including rapid onset of action, long-lasting clinical remission, steroid-free remission, and deep mucosal healing, with a favorable safety profile. In the ENLIGHT UC study, the largest Asian multicenter Phase 3 clinical study, the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%. These findings demonstrate VELSIPITY(R)'s potential to improve long-term disease outcomes and reduce the risk of relapse and disease progression.Results from the ELEVATE UC open-label extension demonstrate continuous treatment with VELSIPITY(R) for up to 3 years resulted in 86.8% of patients achieving a clinical response among the observed cases, with both clinical remission and mucosal healing rates maintained at approximately 60%. Safety data extending up to five years from the global clinical program further confirm that VELSIPITY(R) is well tolerated and maintains a favorable and stable safety profile.Prof. Chen Minhu, Academic Leader of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University, noted that with the first prescription now issued, VELSIPITY(R) is being incorporated into routine clinical practice, providing physicians with an innovative treatment option for patients living with UC who continue to face ongoing disease challenges.“Early achievement of mucosal healing is recognized as a key treatment goal, as it can significantly reduce rates of disease relapse, hospitalization, surgery, and the risk of progression to colorectal cancer. VELSIPITY(R) addresses this need by targeting intestinal inflammation at its source and promoting mucosal healing, while offering a favorable profile of efficacy and safety, along with the convenience of an oral, once-daily regimen, supporting sustained disease management and improving patients' quality of life,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.In 2024 and 2025, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. Real-world data have shown that the efficacy and safety of VELSIPITY(R) are consistent with those observed in clinical trials.From a commercialization perspective, Everest Medicines has already demonstrated a mature and replicable capabilities through its core nephrology product NEFECON(R). As the world’s first and currently the only etiological treatment for IgA nephropathy (IgAN) to receive full approvals in China, the United States, and Europe, Nefecon(R) generated more than RMB 1 billion in sales in the first three quarters of 2025. The product has set a new benchmark for non-oncology therapies and has become one of the best-performing chronic disease drugs added to China’s national reimbursement list over the past decade.This achievement has validated the company’s platform for the commercialization of innovative medicines, centered on the integrated coordination of access, medical, marketing, and sales (A2MS) driven by scientific and commercial insights. It has also provided replicable systems and experience for the market expansion of future products. The rapid issuance of the first prescription for VELSIPITY(R) further demonstrates the efficiency of this platform. Leveraging the channel network and market access experience built through Nefecon(R), the product is expected to replicate a similar growth trajectory.From a market landscape perspective, China’s UC treatment market has long been dominated by traditional immunosuppressants and injectable biologics. However, these therapies present certain limitations, including lack of oral convenience and potential long-term safety risks. With its differentiated advantages, VELSIPITY(R) is widely viewed by the industry as having the potential to address this unmet need. Market expectations suggest that the drug could reach peak sales of RMB 5 billion, becoming a key driver of revenue growth for Everest Medicines.Everest Medicines stated that it plans to build a multi-channel market access framework, provide diversified patient assistance programs and innovative payment solutions, and actively pursue the inclusion of VELSIPITY(R) in China’s National Reimbursement Drug List (NRDL) to improve the drug’s accessibility and affordability. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
香港, 2026年3月11日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（01952.HK）宣布，旗下自身免疫性疾病领域核心产品维适平(R)（精氨酸艾曲莫德片，VELSIPITY(R)）中国大陆首张处方在3月9日于中山大学附属第一医院开出，标志着这款创新疗法正式进入中国临床应用阶段。据悉，在中国大陆首方开具当天，维适平(R)已在广州、上海、杭州、西安、重庆、北京和南京7个核心城市的8家三甲医院同步开出处方，实现上市首日即覆盖全国重点区域患者，并通过互联网医院渠道进一步扩大患者覆盖范围。目前，该药物已在中山大学附属第一医院、浙江大学医学院附属邵逸夫医院、中国人民解放军空军军医大学第一附属医院、重庆市人民医院、中国医学科学院北京协和医院等多家核心医疗机构惠及患者。值得关注的是，维适平(R)于今年2月获得国家药监局批准上市，仅一个月便实现中国大陆首方落地，推进速度明显快于行业平均水平。业内认为，这不仅反映出该产品较高的临床需求，也体现了云顶新耀在创新药商业化方面的执行效率。从疾病负担来看，炎症性肠病（IBD）已被认为是全球增长最快的消化系统疾病之一。IBD主要包括溃疡性结肠炎（UC）和克罗恩病（CD）。近年来，随着饮食结构变化、生活方式改变以及诊断水平提升，中国患者数量持续增加。多家行业研究机构预计，到2030年前后，中国IBD治疗市场规模有望突破百亿元人民币，其中新型小分子创新药将成为主要增长动力之一。从临床需求来看，溃疡性结肠炎是一种病因尚不明确、易复发的慢性肠道炎症性疾病，临床表现为黏液血便、腹痛、腹泻、里急后重等症状，严重影响患者长期生活质量。近年来，中国该病发病率和患病率持续上升且呈年轻化趋势，预计患者人数将由2025年的约98万增长至2031年的约150万。目前该病仍无法治愈，患者需长期用药维持疾病控制，而传统疗法疗效有限、生物制剂存在“疗效天花板”，临床亟需能实现更稳定、持久疾病控制的创新方案。维适平(R)作为每日口服一次的新一代高选择性S1P受体调节剂，具备最佳药物（best-in-disease）潜质，已获得美国胃肠病学协会（AGA）临床实践指南与美国胃肠病学会（ACG）临床指南强烈推荐，作为中重度溃疡性结肠炎的一线用药。多项全球临床研究证实其疗效与安全性良好，尤其在快速起效、实现无激素缓解及深度黏膜愈合方面具有明显临床优势。在迄今最大规模的中重度UC患者亚洲多中心III期临床研究（ENLIGHT UC）中，维适平(R)维持治疗40周，临床缓解率达48.1%，深度黏膜愈合率达51.9%，内镜正常化率达45.5%。数据显示，维适平(R)可实现强效深度黏膜愈合，从而改善疾病长期预后，并有助于降低复发及癌变风险。全球Ⅲ期ELEVATE研究的一项开放标签扩展研究数据证实，持续维适平(R)治疗3年，在观察病例中，86.8%患者实现临床应答，临床缓解率和黏膜愈合率均维持在约60%水平。全球临床研究随访5年的数据进一步表明其稳定且良好的安全性特征，整体耐受性良好。中华医学会消化病学分会前任主任委员、中山大学附属第一医院消化内科学术带头人陈旻湖教授指出，维适平(R)此次首张处方的开具，有望进一步优化溃疡性结肠炎的临床管理路径，推动疾病治疗向更高水平发展，实现黏膜愈合的治疗目标，惠及更多患者。云顶新耀首席执行官罗永庆表示，黏膜愈合是当前溃疡性结肠炎的治疗目标，尽早实现可大幅降低患者疾病复发率、住院率、手术率和癌变风险。维适平(R)可从源头控制肠道炎症，促进黏膜愈合，填补了中重度溃疡性结肠炎治疗领域的空白。作为一款治疗溃疡性结肠炎的创新一线治疗药物，维适平(R)兼具“疗效、安全性及方便性”三重优势，为患者提供长期疾病控制与生活质量改善的保障。此外，该药物于2024年和2025年被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录，在大湾区率先实现临床应用，且在真实诊疗场景中的表现与临床研究疗效、安全性一致。商业化层面，云顶新耀已通过肾科核心产品耐赋康(R)验证了成熟可复制的商业化能力。作为全球首个且目前唯一在中、美、欧获得完全批准的IgA肾病对因治疗药物，耐赋康(R)在2025年前三季度销售额突破10亿元，创造了非肿瘤产品的历史，成为过去十年慢病药进医保销售最好的产品。该产品的成功，验证了以“科学及商业洞察驱动的准入、医学、市场、销售一体化协同（A2MS）”为核心的创新药商业化运营平台，也为后续产品的市场拓展提供了可复用的体系与经验。此次维适平(R)首方快速落地，进一步印证了该平台的高效性，依托耐赋康(R)的渠道网络与市场准入经验，其有望复刻增长路径。从市场格局来看，长期以来中国溃疡性结肠炎治疗市场以传统免疫抑制剂和注射型生物制剂为主，这些方案存在口服便利性不足、长期安全性风险等问题。维适平(R)凭借差异化优势，被业界认为有望填补这一需求缺口，行业普遍预期其销售峰值可达50亿元，成为驱动云顶新耀业绩增长的重要引擎。云顶新耀表示，将构建多渠道准入体系，提供多元化患者援助项目和创新支付方案，并全力推动维适平(R)纳入国家医保目录，以提升药物的可及性和可负担性。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), MarketingPulse and eTailingPulse – Asia’s premier annual e-commerce and marketing events – will be held concurrently on 19 March at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme "Generate New Growth", this year's conferences focus on how brands can rethink their growth strategies amid global market uncertainty, helping to turn challenges into forward momentum. From strategic insights to practical implementation, the events will comprehensively reveal new directions for growth, bringing together about 70 global e-commerce experts, marketing executives, brand representatives and advertising elites to share valuable insights and success stories relating to global marketing and e-commerce trends. Featuring 30 thematic sessions, seminars and demonstration sessions, the events will help to foster cross-sector exchange and boost collaboration within the industry.The rise of e-commerce has injected new momentum into global economic growth, while the government is actively encouraging small and medium-size enterprises (SMEs) to develop e-commerce capabilities that can enhance their market competitiveness. This year’s conferences will focus on the latest developments in e-commerce, helping participants seize growth opportunities in the current market environment through a dual-track approach that advances both e-commerce development and brand marketing. A lineup of experts will speak on topics such as agentic AI, lifestyle e-commerce, quick commerce and global brand expansion. They will examine innovation in e-commerce along with global marketing trends and emerging consumer opportunities, while exploring how the industry can generate new growth amid a rapidly evolving marketing landscape.Tech marketing expert shares insights on data-driven growthJinhee Lee, Chief Operating Officer of Olive Young, South Korea’s leading health and beauty brand, will present on the theme “Beyond Retail, Building an Ecosystem: Driving Collaborative Growth of Olive Young and K-Beauty”. Drawing on perspectives from both marketing and e-commerce, he will explain how seamless omnichannel operations and data-driven marketing strategies are being leveraged to build a high-growth ecosystem for Korean beauty brands, while continuously expanding their global footprint. Well-known for harnessing data to drive innovation, Mr Lee has spearheaded a series of digital transformation initiatives and integrated retail strategies, using technology to enable Olive Young to stay ahead of trends and become a leader in the global beauty market.Breaking new ground in marketing through the China experience and new retailAtour Group is a leading player in Chinese Mainland’s mid- to high-end hotel chain market. Its Founder, CEO & Chief Experience Officer, Haijun Wang, will focus on two key themes during his presentation: 1) Experience Differentiation Strategy — placing differentiated experiences at the core to build distinctive product and service offerings across both the hotel and retail businesses; and 2) Customer Segment Operations Strategy — using a core customer base that pursues a quality lifestyle as the connective thread to deeply integrate the hotel and retail businesses, thereby shaping a unique brand group model.Enhancing brand value through aesthetic intelligence in e-commercePauline Brown, former Chairman of LVMH North America, will share how to leverage "aesthetic intelligence" to elevate brand value, shape consumer perception and strengthen overall online-to-offline experiences and marketing strategies. She will also discuss how brands can continuously cultivate "taste" and aesthetic acumen and explain how aesthetics and elevated storytelling can be utilised to build truly compelling brands in a rapidly changing e-commerce and technological landscape.Exploring the latest trends in agentic AI and quick commerceQuick commerce and agentic AI are bringing unprecedented changes to the e-commerce market in the Chinese Mainland, continuously reshaping consumers' shopping patterns, habits and demands. Yatong Qiu, Vice President of Taobao&Tmall Group, Alibaba, will share on how brands and merchants can tackle demand through flexible merchandising strategies, real-time marketing and speed-oriented innovations to maintain competitiveness and seize time-sensitive opportunities. Meanwhile, Terry Li, Vertical General Manager of Smart Retail, Tencent, will take a deeper dive into agentic AI-driven e-commerce strategies. Looking from the perspectives of service providers and e-commerce ecosystems, he will share practical approaches and future innovation directions for agentic AI solutions, helping brands and businesses seize the initiative in the new era of e-commerce.Decoding cross-border growth and market entry strategies for ASEANAs ASEAN continues to rise as one of the world's most dynamic economic regions, enterprises from the Chinese Mainland and Hong Kong are actively setting their sights on Southeast Asia, particularly seeking growth opportunities through e-commerce channels. The conferences will feature a session titled “Decoding the Gateway to ASEAN: Cross Border Growth and Market Entry Strategies”, exploring strategies for entering the ASEAN market. Speakers including Luca Barni, SVP, Commercial, Lazada Group, will share their practical experiences in expanding within ASEAN. Attendees will get a comprehensive understanding of the growth opportunities and common pitfalls in this growing market, addressing e-commerce legal and regulatory challenges, as well as brand and product localisation strategies.Cracking the Threads audience engagement plus celebrity insightsThe recent rise of social platform Threads is further driving the evolution of brand marketing models. In the "Threads for Consumer and Audience Engagement" session, Kenie Kwok, Creative Strategy Lead at Meta, will share the latest trends in brand account management and user preferences from the platform's perspective. Actor and "Threads Admin" Ng Siu-hin will share his insights on how to stand out as a content creator, offering practical tips on building engagement with netizens from a creator's viewpoint. In addition, IN.DECIDE, renowned for managing social media platforms for multiple brands as an "admin", will analyse its promotional campaign for the film Peg O' My Heart, detailing how the virtual character "Choi San-keung" successfully broke the fourth wall with the audience.This year's "Meet the Celebrity” dialogue series has invited actor and singer-songwriter Louis Cheung to speak on the topic "Chasing the Golden Boy Within". He will share his career journey in personal brand management and talk about his multifaceted development across the acting, music and creative fields. Meanwhile, content creator and MUSE TV Founder Mayao will discuss how he strategically leverages innovative promotional approaches to market music works, generating broad and lasting public impact and driving sustainable market growth.Exploring the “healing economy" and IP marketingWhen engaging with younger generations, who place strong emphasis on emotional connection, brands must understand “oshikatsu culture”, where young people identify strongly as a fan of an idol, along with the healing trend and intellectual property (IP)-driven consumer behaviour. The session "Healing Economy and IP Marketing" will feature speakers including Yiying Wang, Founder and Designer of Noodoll Limited, who will explore how brands can keep abreast of the latest trends, such as designing sustainably interactive experiences and campaigns with an "oshikatsu mindset", incorporating healing elements into products or marketing to enhance resonance, and collaborating with popular IPs to boost reach and engagement, thereby deepening connections and relationships with younger demographics.The conferences will introduce a new feature, "e-Commerce Connect", showcasing the latest one-stop e-commerce solutions, with close to 30 local and international exhibitors. Additionally, a series of digital marketing and e-commerce workshops will enable participating brands to gain hands-on practical experience. Multiple networking activities will be organised, and participants can take advantage of one-to-one business matching services to facilitate cross-sector exchange and collaboration. The event will also feature live music performances, including a set from popular local singer James Ng.For more information on speakers and the detailed programme for the conferences, please visit: https://marketingpulse.hktdc.com/conference/mp/en. To request interviews with guest speakers, please email betsytse@raconteur.hk or molisalau@raconteur.hk.Photo download: https://bit.ly/3OU0UArPauline Brown, Former Chairman of LVMH North AmericaHaijun Wang, Founder and CEO of Atour Lifestyle HoldingsJinHee Lee, Chief Operating Officer of Olive YoungLouis Cheung, Actor and singer-songwriterNg Siu-hin, Artist and "Threads Admin"MarketingPulse and eTailingPulse will be held on 19 March at the Hong Kong Convention and Exhibition Centre. Pictured are the MarketingPulse and eTailingPulse events held in 2025Websites· MarketingPulse: https://marketingpulse.hktdc.com/conference/mp/en· Event schedule: https://marketingpulse.hktdc.com/conference/mp/en/programme· Speaker list: https://marketingpulse.hktdc.com/conference/mp/en/speaker· eTailingPulse: https://etailingpulse.hktdc.com/conference/etp/en· EntertainmentPulse: https://hkfilmart.hktdc.com/conference/hkfilmart/en Media enquiriesFor enquiries, please contact:Raconteur PR Agency:Betsy TseTel: (852) 9742 7338Email: betsytse@raconteur.hkMolisa LauTel: (852) 6187 7786Email: molisalau@raconteur.hkHKTDC Communication and Public Affairs Department:Clayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TOKYO, Mar 11, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD), at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab data and additional research findings from Eisai’s AD portfolio will be featured in six presentations, including three oral presentations. Eisai will host an industry-sponsored symposium.Oral and Poster PresentationsOral presentations will include the latest findings from a United States real-world long-term treatment persistence study, and efficacy and safety outcomes in apolipoprotein E ε4 (ApoEε4) homozygous carriers in a U.S. multicenter real-world study. In addition, four-year data from the Clarity AD Open-Label Extension trial in ApoEε4 non-carriers and heterozygotes, and a genome-wide association study on novel genetic variants associated with cognitive decline in AD will be presented as posters.Eisai Symposium – Continue Life Their Way: Early Intervention in Alzheimer’s DiseaseEisai is sponsoring a symposium featuring four leading global experts in the field of AD, on the topics of why early intervention matters, continuing early AD treatment and real-world outcomes. The symposium aims to enhance understanding of the value of early and continued anti-amyloid treatment in early AD by exploring how real-world evidence can support confident patient assessment in clinical practice, and how to recognize AD as a chronic condition that requires a multidisciplinary approach to care.Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.AD/PD 2026 Presentations Relating to Eisai's Key Compounds and ResearchFor more information, please visit: https://www.eisai.com/news/2026/pdf/enews202612pdf.pdfMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120Eisai Europe, Ltd.(Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 7739-600-678EMEA-comms@eisai.netEisai, Inc. (U.S.)Julie Edelman+1-862-213-5915Julie Edelman@eisai.comAbout Lecanemab (generic name, brand name: Leqembi)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 10 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilsProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.¹ Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.²About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies cocommercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.References1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12: 3451. doi:10.1038/s41467-021-23507-z.2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
SINGAPORE, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – JOYY Inc. (NASDAQ: JOYY) announced its unaudited financial results for the fourth quarter and full year of 2025.In the fourth quarter of 2025, JOYY’s total revenue was US$581.9 million, up 7.7% quarter over quarter and 5.9% year over year, marking a return to year-over-year revenue growth. Livestreaming revenue was US$394.4 million, up 1.5% quarter over quarter, marking the third consecutive quarter of sequential growth. BIGO Ads delivered accelerating revenue growth, up 61.5% year over year to US$128.1 million. For the full year of 2025, total revenue was US$2.12 billion. Livestreaming contributed US$1.53 billion, while BIGO Ads contributed US$398.5 million, up 38.5% year over year, driving total non-livestreaming revenue, including ad revenue and others, to 28.0% of the Company’s revenue, up 7.9 percentage points from 2024.In 2025, JOYY delivered steady profitability growth. Non-GAAP[1] operating income and non-GAAP[1] EBITDA were US$150.8 million and US$189.8 million, up 10.8% and 10.9% year over year, respectively. In the fourth quarter, non-GAAP1 operating income stood at US$40.8 million, and operating cash flow for the fourth quarter totaled US$116.0 million. As of December 31, 2025, the Company held US$3.26 billion in net cash.JOYY previously announced a shareholder return program of approximately US$900 million through dividends and share repurchases from 2025 through 2027. The Company has been actively executing its share repurchase program, with repurchases totaling US$67.4 million in the fourth quarter. In total, JOYY has distributed approximately US$332.0 million in dividends and share repurchases throughout 2025. In light of the double-digit improvements in operational profit in 2025, the Company will distribute an additional cash dividend of approximately US$20 million in the first quarter of 2026.Fourth Quarter 2025 Financial Highlights- Net revenues increased by 5.9% to US$581.9 million from US$549.4 million in the corresponding period of 2024 and by 7.7% from US$540.2 million in the third quarter of 2025.Livestreaming revenue was US$394.4 million, representing an increase of 1.5% from US$388.5 million in the third quarter of 2025.Advertising revenue increased by 62.4% to US$145.4 million from US$89.6 million in the corresponding period of 2024 and by 29.3% from US$112.5 million in the third quarter of 2025.Other revenues increased by 12.3% to US$42.1 million from US$37.5 million in the corresponding period of 2024 and by 7.2% from US$39.2 million in the third quarter of 2025.- Operating income was US$18.3 million.- Non-GAAP1 operating income was US$40.8 million.- Net Cash as of December 31, 2025 was US$3.26 billion.- Net cash from operating activities was US$116.0 million, compared with US$110.5 million in the corresponding period of 2024.Full Year 2025 Financial Highlights- Net revenues were US$2,124.2 million.- Operating income was US$55.8 million.- Non-GAAP1 operating income was US$150.8 million, up 10.8% from US$136.1 million in 2024.- Non-GAAP1 EBITDA was US$189.8 million, up 10.9% from US$171.2 million in 2024.[1]This press release includes certain non-GAAP financial measures as additional clarifying items to aid investors in further understanding the Company's performance and the impact that these items and events had on the financial results. The non-GAAP financial measures provided above should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP. For details of the non-GAAP measures, including the reconciliations of GAAP measures to non-GAAP measures, please refer to the press release titled “JOYY Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results” issued by the Company on March 11, 2026. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
